Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)

Jaume Capdevila; Virginia Pubul; Urbano Anido; Thomas Walter; Javier Molina‑Cerrillo; Teresa Alonso‑Gordoa; Rocio Garcia‑Carbonero; Maria San‑Roman‑Gil; Belen Llana; Paula Jimenez‑Fonseca; Marta Benavent Viñuales; Catherine Ansquer; Eric Baudin; Come Lepage; Maribel del Olmo‑García; José Carlos Ruffinelli; Amandine Beron; Magalie Haissaguerre; Emmanuel Deshayes; David Taïeb; Sergio Baldari; Maddalena Sansovini; Sara Cingarlini; Angelina Filice; Francesco Panzuto; Rosa Álvarez‑Álvarez; Laurence Lousberg; Frank Aboubakar Nana; Jorge Hernando; Alejando García‑Álvarez; Amparo García‑Burillo; Guillermo Villacampa; Timon Vandamme; Nicola Fazio; Alice Durand

doi:10.1186/s12885-026-16297-4

. 2026 Jun 13;26:747. doi: 10.1186/s12885-026-16297-4

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)

Jaume Capdevila ^1,^✉, Virginia Pubul ², Urbano Anido ³, Thomas Walter ⁴, Javier Molina‑Cerrillo ⁵, Teresa Alonso‑Gordoa ⁵, Rocio Garcia‑Carbonero ^6,^7,⁸, Maria San‑Roman‑Gil ⁶, Belen Llana ⁹, Paula Jimenez‑Fonseca ¹⁰, Marta Benavent Viñuales ¹¹, Catherine Ansquer ¹², Eric Baudin ¹³, Come Lepage ¹⁴, Maribel del Olmo‑García ^15,¹⁶, José Carlos Ruffinelli ¹⁷, Amandine Beron ¹⁸, Magalie Haissaguerre ¹⁹, Emmanuel Deshayes ²⁰, David Taïeb ²¹, Sergio Baldari ²², Maddalena Sansovini ²³, Sara Cingarlini ²⁴, Angelina Filice ²⁵, Francesco Panzuto ²⁶, Rosa Álvarez‑Álvarez ²⁷, Laurence Lousberg ²⁸, Frank Aboubakar Nana ^29,³⁰, Jorge Hernando ¹, Alejando García‑Álvarez ¹, Amparo García‑Burillo ¹, Guillermo Villacampa ³¹, Timon Vandamme ^32,³³, Nicola Fazio ³⁴, Alice Durand ⁴

¹Medical Oncology Department. Vall, Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain

²Department of Nuclear Medicine, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain

³Molecular Imaging Research Group, Nuclear Medicine Department, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain

⁴Medical Oncology Department, Edouard Herriot Hospital, Lyon, France

⁵Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain

⁶Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain

⁷Center of Experimental Oncology. Gastrointestinal and Neuroendrocrine Tumors Research Group, Hospital 12 de Octubre Research Institute (Imas12), Madrid, Spain

⁸Facultad de Medicina, Departamento de Medicina, Universidad Complutense de Madrid (UCM), Madrid, Spain

⁹Nuclear Medicine Department, Hospital Universitario Central de Asturias, Oviedo, Spain

¹⁰Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain

¹¹Medical Oncology Department, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain

¹²Service de Médecine Nucléaire, CHU de Nantes, Nantes Université, Nantes, France

¹³Department of Endocrine Oncology and Nuclear Medicine, Gustave Roussy Cancer Campus Grand Paris, Villejuif, France

¹⁴Department of Digestive Oncology, University Hospital Dijon, University of Burgundy and Franche Comté, Dijon, France

¹⁵Endocrinology and Nutrition Department, Endocrinology, Nutrition and Diet Therapy, Research Unit, University and Polytechnic Hospital La Fe, Valencia, Spain

¹⁶Departamento de Medicina, Universidad de Valencia, Valencia, Spain

¹⁷Medical Oncology Department, Institut Català d’Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain

¹⁸Service de Médecine Nucléaire, Hôpital Claude Huriez, CHU Lille, Lille, France

¹⁹Department of Endocrinology, University of Bordeaux, Bordeaux, France

²⁰Department of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, Cedex 5 France

²¹Department of Nuclear Medicine, Aix-Marseille University, La Timone University Hospital, Marseille, France

²²Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and of Morpho‑Functional Imaging, University of Messina, Messina, Italy

²³Therapeutic Nuclear Medicine, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) ‘’Dino Amadori’’, Meldola, Italy

²⁴Medical Oncology, University and Hospital Trust of Verona, Verona, Italy

²⁵Servizio Di Medicina Nucleare, Azienda USL-IRCCS Di Reggio Emilia, Reggio Emilia, Italy

²⁶Department of Medical‑Surgical Sciences and Translational Medicine, Sapienza University of Rome, Digestive Disease Unit, ENETS Center of Excellence, Sant’Andrea University Hospital, Rome, Italy

²⁷Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain

²⁸Service d’Oncologie Médicale CHU Liège, Liège, Belgium

²⁹Department of Pulmonology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, 1200 Belgium

³⁰Institut de Recherche Expérimentale Et Clinique (IREC), Université Catholique de Louvain, Brussels, 1200 Belgium

³¹Statistics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

³²Department of Oncology and Netwerk, University Hospital Antwerp, Edegem, Belgium

³³Center for Oncological Research, Integrated Personalized &Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium

³⁴Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy

^✉

Corresponding author.

PMCID: PMC13264813 PMID: 42288752

Correction: BMC Cancer 25, 613 (2025)

https://doi.org/10.1186/s12885-025-13941-3

Following publication of the original article [1], it has been decided to update the Competing interest to reflect the below changes.

Remove “The remaining authors declare that they have no competing interests.”
Add “DT is a co-founder, stakeholder, and Chief Medical Officer (CMO) of SILON Therapeutics.”

The original article has been updated.

References

1.Capdevila J, Pubul V, Anido U, et al. A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). BMC Cancer. 2025;25:613. 10.1186/s12885-025-13941-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR1] 1.Capdevila J, Pubul V, Anido U, et al. A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). BMC Cancer. 2025;25:613. 10.1186/s12885-025-13941-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)

Jaume Capdevila

Virginia Pubul

Urbano Anido

Thomas Walter

Javier Molina‑Cerrillo

Teresa Alonso‑Gordoa

Rocio Garcia‑Carbonero

Maria San‑Roman‑Gil

Belen Llana

Paula Jimenez‑Fonseca

Marta Benavent Viñuales

Catherine Ansquer

Eric Baudin

Come Lepage

Maribel del Olmo‑García

José Carlos Ruffinelli

Amandine Beron

Magalie Haissaguerre

Emmanuel Deshayes

David Taïeb

Sergio Baldari

Maddalena Sansovini

Sara Cingarlini

Angelina Filice

Francesco Panzuto

Rosa Álvarez‑Álvarez

Laurence Lousberg

Frank Aboubakar Nana

Jorge Hernando

Alejando García‑Álvarez

Amparo García‑Burillo

Guillermo Villacampa

Timon Vandamme

Nicola Fazio

Alice Durand

References

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases